In a previous work, we began to follow the early dynamics of CTCs using 3D telomere analysis during ADT (a pilot study composed of 20 patients, where consenting treatment-naïve patients with cT3, Gleason 8-10, or prostate-specific antigen > 20 ng/mL and non-metastatic prostate cancer were included) [19]. The gene discussed is KLK3; the disease is metastatic prostate carcinoma.